- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 43 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| Fr | Intensity Therapeutics GAAP EPS of -$8.56 misses by $0.69 | 3 | Seeking Alpha | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | INTENSITY THERAPEUTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| Di | Intensity Therapeutics erhält neues US-Patent für Krebstherapie | 3 | Investing.com Deutsch | ||
| Mo | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause | 3 | Benzinga.com | ||
| 12.03. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | 203 | PR Newswire | Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care... ► Artikel lesen | |
| 12.03. | Intensity Therapeutics reports early trial data in breast cancer | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics erfüllt wieder NASDAQ-Anforderungen | 10 | Investing.com Deutsch | ||
| 06.03. | Intensity Therapeutics regains Nasdaq compliance | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement | 2 | Seeking Alpha | ||
| 06.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 156 | PR Newswire | SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company... ► Artikel lesen | |
| 05.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 13.02. | Intensity Therapeutics announces 1-for-25 reverse stock split | 21 | Investing.com | ||
| 13.02. | Intensity Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:25 an | 4 | Investing.com Deutsch | ||
| 13.02. | Intensity Therapeutics Inc.: Intensity Therapeutics Announces Reverse Stock Split | 228 | PR Newswire | Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026
SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity... ► Artikel lesen | |
| 23.01. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 13.01. | Intensity Therapeutics legt nach klinischer Validierung Strategie für 2026 fest | 6 | Investing.com Deutsch | ||
| 13.01. | Intensity Therapeutics Inc.: Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | 261 | PR Newswire | Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026
SHELTON, Conn., Jan. 13, 2026 /PRNewswire/... ► Artikel lesen | |
| 05.12.25 | Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance | 13 | Seeking Alpha |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 74,50 | -1,84 % | BioNTech Aktie: Panik war gestern! Gründer weg, Kurs im Keller und trotzdem könnte es jetzt ein gutes Investment sein! | © Foto: von Mathurin NAPOLY / matnapo auf Unsplash (Symbolbild)Die Nachricht schlug ein wie eine Bombe: Das Gründerduo Ugur Sahin und Özlem Türeci verlässt BioNTech. Die Reaktion an der Börse war ein... ► Artikel lesen | |
| NOVAVAX | 7,791 | -0,93 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 39,600 | -3,88 % | AtaiBeckley added to S&P Total Market, CRSP benchmark indices | ||
| EDITAS MEDICINE | 2,041 | +0,79 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| GINKGO BIOWORKS | 5,250 | -7,08 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business | Ginkgo provides an update on its fourth quarter financial results
BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today... ► Artikel lesen | |
| NOVOCURE | 10,155 | -0,44 % | Novocure Reports Positive Topline Results From Phase 2 PANOVA-4 Trial Of TTFields Therapy | WASHINGTON (dpa-AFX) - Novocure (NVCR) announced Thursday positive results from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq)... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,012 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ARTELO BIOSCIENCES | 10,510 | +229,47 % | Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate... ► Artikel lesen | |
| QIAGEN | 33,900 | -3,32 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,250 | +11,58 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ERASCA | 14,980 | -1,19 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| ONCONETIX | 1,890 | -41,30 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS68237Q2030 Onconetix Inc. 24.03.2026 US68237Q3020 Onconetix Inc. 25.03.2026 Tausch 5:1US98386D3070 XTL Biopharmaceuticals... ► Artikel lesen | |
| ARCELLX | 114,56 | -0,07 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| APOGEE THERAPEUTICS | 77,85 | -0,74 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,890 | -3,43 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen |
Das Unternehmen INTENSITY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.